Abstract
NAFLD is a population disease that can be primarily considered a marker of cardiovascular risk. Despite the relatively small risk of progression of liver disease into more advanced stages, including cirrhosis, it is also a significant hepatologic problem due to its high incidence in the population..
Non-invasive diagnostic methods can be used in the search for people with more advanced forms of the disease, especially in primary care - either on the principle of calculated indices from laborato- ry-determined biomarkers or some of the elastographic methods. At the moment, the basis of therapy is an effort to influence the lifestyle and reduce weight.
Pharmacotherapeutic treatment options are currently limited and should be reserved for selected patients with NASH with a higher stage of fibrosis